search icon
trvi-img

Trevi Therapeutics Inc, Common Stock

TRVI

NMQ

$6.36

+$0.1

(1.6%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$613.52M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
821.90K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.62
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.3 L
$7.39 H
$6.36

About Trevi Therapeutics Inc, Common Stock

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameTRVISectorS&P500
1-Week Return5.47%0.71%0.79%
1-Month Return0.79%-5.6%6.04%
3-Month Return40.71%-11.72%-1.11%
6-Month Return120.83%-10.81%-2.39%
1-Year Return150.39%-7.12%11.69%
3-Year Return162.81%-0.57%42.29%
5-Year Return132.12%27.64%93.12%
10-Year Return-19.39%75.45%179.21%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue47.00K50.00K43.00K123.00K-[{"date":"2020-12-31","value":38.21,"profit":true},{"date":"2021-12-31","value":40.65,"profit":true},{"date":"2022-12-31","value":34.96,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(47.00K)(50.00K)(43.00K)(123.00K)-[{"date":"2020-12-31","value":-4700000,"profit":false},{"date":"2021-12-31","value":-5000000,"profit":false},{"date":"2022-12-31","value":-4300000,"profit":false},{"date":"2023-12-31","value":-12300000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)-[{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses32.49M32.48M29.91M33.92M51.52M[{"date":"2020-12-31","value":63.06,"profit":true},{"date":"2021-12-31","value":63.03,"profit":true},{"date":"2022-12-31","value":58.04,"profit":true},{"date":"2023-12-31","value":65.84,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(32.49M)(32.48M)(29.91M)(33.92M)(51.52M)[{"date":"2020-12-31","value":-3248900000,"profit":false},{"date":"2021-12-31","value":-3247600000,"profit":false},{"date":"2022-12-31","value":-2990700000,"profit":false},{"date":"2023-12-31","value":-3392300000,"profit":false},{"date":"2024-12-31","value":-5152400000,"profit":false}]
Total Non-Operating Income/Expense(565.00K)(2.68M)1.30M8.89M7.18M[{"date":"2020-12-31","value":-6.35,"profit":false},{"date":"2021-12-31","value":-30.1,"profit":false},{"date":"2022-12-31","value":14.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":80.75,"profit":true}]
Pre-Tax Income(32.78M)(33.96M)(29.19M)(29.10M)(47.94M)[{"date":"2020-12-31","value":-3277600000,"profit":false},{"date":"2021-12-31","value":-3396100000,"profit":false},{"date":"2022-12-31","value":-2918800000,"profit":false},{"date":"2023-12-31","value":-2909700000,"profit":false},{"date":"2024-12-31","value":-4794100000,"profit":false}]
Income Taxes(18.00K)(21.00K)(36.00K)(32.00K)(30.00K)[{"date":"2020-12-31","value":-1800000,"profit":false},{"date":"2021-12-31","value":-2100000,"profit":false},{"date":"2022-12-31","value":-3600000,"profit":false},{"date":"2023-12-31","value":-3200000,"profit":false},{"date":"2024-12-31","value":-3000000,"profit":false}]
Income After Taxes(32.76M)(33.94M)(29.15M)(29.07M)(47.91M)[{"date":"2020-12-31","value":-3275800000,"profit":false},{"date":"2021-12-31","value":-3394000000,"profit":false},{"date":"2022-12-31","value":-2915200000,"profit":false},{"date":"2023-12-31","value":-2906500000,"profit":false},{"date":"2024-12-31","value":-4791100000,"profit":false}]
Income From Continuous Operations(32.76M)(33.94M)(29.15M)(26.75M)(47.91M)[{"date":"2020-12-31","value":-3275800000,"profit":false},{"date":"2021-12-31","value":-3394000000,"profit":false},{"date":"2022-12-31","value":-2915200000,"profit":false},{"date":"2023-12-31","value":-2674900000,"profit":false},{"date":"2024-12-31","value":-4791100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(32.76M)(33.94M)(29.15M)(29.07M)(47.91M)[{"date":"2020-12-31","value":-3275800000,"profit":false},{"date":"2021-12-31","value":-3394000000,"profit":false},{"date":"2022-12-31","value":-2915200000,"profit":false},{"date":"2023-12-31","value":-2906500000,"profit":false},{"date":"2024-12-31","value":-4791100000,"profit":false}]
EPS (Diluted)(1.81)(1.52)(0.56)(0.29)(0.47)[{"date":"2020-12-31","value":-181,"profit":false},{"date":"2021-12-31","value":-152,"profit":false},{"date":"2022-12-31","value":-56,"profit":false},{"date":"2023-12-31","value":-29,"profit":false},{"date":"2024-12-31","value":-47,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

TRVI
Cash Ratio 15.04
Current Ratio 15.38

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

TRVI
ROA (LTM) -34.41%
ROE (LTM) -55.12%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

TRVI
Debt Ratio Lower is generally better. Negative is bad. 0.07
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.93

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

TRVI
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 6.51
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Trevi Therapeutics Inc share price today?

Trevi Therapeutics Inc (TRVI) share price today is $6.36

Can Indians buy Trevi Therapeutics Inc shares?

Yes, Indians can buy shares of Trevi Therapeutics Inc (TRVI) on Vested. To buy Trevi Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TRVI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Trevi Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Trevi Therapeutics Inc (TRVI) via the Vested app. You can start investing in Trevi Therapeutics Inc (TRVI) with a minimum investment of $1.

How to invest in Trevi Therapeutics Inc shares from India?

You can invest in shares of Trevi Therapeutics Inc (TRVI) via Vested in three simple steps:

  • Click on Sign Up or Invest in TRVI stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Trevi Therapeutics Inc shares
What is Trevi Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Trevi Therapeutics Inc (TRVI) is $7.39. The 52-week low price of Trevi Therapeutics Inc (TRVI) is $2.3.

What is Trevi Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Trevi Therapeutics Inc (TRVI) is 6.51

What is the Market Cap of Trevi Therapeutics Inc?

The market capitalization of Trevi Therapeutics Inc (TRVI) is $613.52M

What is Trevi Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Trevi Therapeutics Inc is TRVI

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top